Cardiovascular Endocrinology

A combination of conditions that together increase the risk of Cardiovascular Disease (CVD). Increase in worldwide prevalence of obesity-associated diabetes, dyslipidemia and hypertension makes it imperative that endocrinologists, cardiologists and others have a forum for new treatment and therapeutic developments. Patients with diabetes are at increased risk of developing a number of serious microvascular and macrovascular complications. Across all ages, the relative risk of developing cardiovascular disease (CVD) is ∼2 for patients with diabetes compared with the general population and CVD contributes significantly to the increased, albeit decreasing over time, mortality rate. Still, CVD accounts for up to 50% of deaths in patients with diabetes. The American Heart Association (AHA) predicts that by 2030, 40.5% of the US population will likely have some form of a CVD, and that the direct cost of treating CVDs will triple from $273 billion in 2010 to $818 billion in 2030; with indirect costs expected to increase from $172 billion to $276 billion in the same time period. These statistics are significant because Americans are developing diabetes and CVD at much younger ages than ever, due to overweight or obesity. Metabolic syndrome doubles the risk of CVD and quintuples the diabetes risk. Risk is especially high in men older than age 45 and women older than age 55.

    Related Conference of Cardiovascular Endocrinology

    Cardiovascular Endocrinology Conference Speakers